Cytoflavin

PreclinicalSmall molecule

PPOLYSAN Scientific & Technological Pharmaceutical Company

Cytoflavin is one of 36 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Atorvastatin Calcium

Merck & Co.

Phase 3

1 2

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 3

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 4

Aggrastat

MMedicure

Phase 3

4 5

Zastaprazan

YYonsei University

Phase 3

1 6

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 7

Proamatine

Takeda

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

3 9

Tylenol

KKenvue Brands

Preclinical

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cytoflavin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytoflavin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytoflavin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — POLYSAN Scientific & Technological Pharmaceutical Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPOLYSAN Scientific & Technological Pharmaceutical Company

Cytoflavin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stroke2 trials

Efficacy and Safety1 trial

Head Trauma1 trial

Diabetic Polyneuropathy1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News